Sydney Eye Hospital

Running trials

• Not yet recruiting

  Baerveldt Versus Paul Study

  NCT07733453· Phase 4· Source

• Recruiting

  A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT07029945· Phase 1/2· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Source

• Not yet recruiting

  First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)

  NCT07766473· Phase 1/2· Source

• Recruiting

  Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

  NCT07266584· Source

• Recruiting

  A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT07118241· Phase 2· Source

• Recruiting

  Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema

  NCT06825702· Phase 2· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

  NCT06770933· Phase 2· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Source

• Active, not recruiting

  A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

  NCT06248619· Phase 3· Source

• Active, not recruiting

  A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

  NCT04850118· Phase 2/3· Source

• Active, not recruiting

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

  NCT06116916· Phase 2· Source

• Active, not recruiting

  VividWhite Glaucoma Implant (VW-51) Pivotal Study

  NCT06176170· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration3 recruiting
• Glaucoma1 recruiting
• Retinitis pigmentosa1 recruiting
• Sjögren's disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT06520202· Phase 1/2· Source

• Completed

  A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

  NCT06384547· Phase 3· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Source

• Completed

  A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

  NCT05176639· Phase 3· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy

  NCT04576689· Phase 2· Source